Impact of participation in randomized trials of reperfusion therapy on the time to reperfusion and hospital mortality in ST-segment elevation myocardial infarction: A single-centre cohort study

Abstract

Aim:

There is uncertainty as to whether consenting and randomizing patients in randomized clinical trials (RCTs) in acute ST-segment elevation myocardial infarction (STEMI) delays reperfusion and increases mortality. The aim of this study was to determine whether participation of patients with STEMI in RCTs is associated with delay in implementation of reperfusion therapy and increased hospital mortality.

Methods and results:

A consecutive sample of 2523 patients, admitted within 6 hours of symptom onset without cardiogenic shock, was recruited from a single tertiary academic centre. They were categorized according to participation (n=392, 15.5%) or nonparticipation (n=2131, 84.5%) in RCTs of reperfusion therapy. Primary outcome was hospital mortality. Additional outcome was time from symptom onset to receipt of reperfusion therapy. Trial participants were more likely to receive fibrinolysis with a 37 min delay in comparison with patients not included in RCTs. Time from symptom onset to reperfusion (minutes) was longer for trial participants than nonparticipants (246±85 vs 233±93, p=0.01). Hospital mortality was 3.61% for nonparticipants. Expected mortality (based on risk modeling) for trial participants was 2.74% (p=0.014 vs nonparticipants). Observed mortality was 1.53% (p=0.034 vs nonparticipants; p=0.16 vs expected mortality). In a multivariable analysis using logistic regression, participation in a RCT was not an independent correlate of hospital mortality (odds ratio 0.54, 95% confidence interval 0.23–2.43, p=0.16).

Conclusions:

In this consecutive cohort, despite a longer delay to reperfusion, there was no indication that participation in a RCT, starting before initiation of reperfusion therapy, was associated with a detectable increase in risk of hospital mortality among patients with STEMI. These data suggest that it is possible to consent and randomize patients with STEMI into RCTs without jeopardizing their survival.

Keywords

Randomized trials acute myocardial infarction primary coronary angioplasty

Get full access to this article

View all access options for this article.

References

Shahzad

Kemp

Mars

. for the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomized controlled trial. Lancet 2014; 384: 1849–1858.

Juliard

Golmard

Ducrocq

. Universal reperfusion therapy can be implemented: lessons from 20 years of management of patients admitted within 6 hours of symptom onset with ST-segment elevation acute myocardial infarction. Arch Cardiovasc Dis 2009; 102: 259–267.

Rothwell

. External validity of randomised controlled trials: ‘To whom do the results of this trial apply?’. Lancet 2005; 365: 82–93.

Brown

Melville

Gray

. Relevance of clinical trial results in myocardial infarction to medical practice: comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysis. Heart 1999; 81: 598–602.

Steg

López-Sendon

Lopez de Sa

. for the GRACE Investigators. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007; 167: 68–73.

Udell

Wang

. Clinical trial participation after myocardial infarction in a national cardiovascular data registry. JAMA 2014; 314; 841–843.

Halkin

Stone

Grines

. Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (The CADILLAC Registry). Am J Cardiol 2005; 96: 1649–1655.

Menees

Peterson

Wang

. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med 2013; 369: 901–909.

Granger

Goldberg

Dabbous

. Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345–2353.